Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
POLH
REST API REST API
Homo sapiens
POLH is differentially expressed in 240 experiments: 100 organism parts: mammary gland, blood, ... (98 more);, 143 disease states: normal, control, ... (141 more);, 80 cell types 386 cell lines 35 compound treatments and 72 other conditions.
Synonyms XP-V, RAD30A
Orthologs POLH (Bos taurus)   POLH (Gallus gallus)   POLH (Danio rerio)   ENSCING00000000016 (Ciona intestinalis)   Polh (Rattus norvegicus)   Polh (Mus musculus)   REV1 (Saccharomyces cerevisiae)   DNApol-eta (Drosophila melanogaster)   POLH (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA repair, cytoplasm, damaged DNA binding, metal ion binding, nucleus, DNA-directed DNA polymerase activity, transferase activity, postreplication repair, nucleoplasm, DNA synthesis involved in DNA repair, DNA replication, nucleotidyltransferase activity, pyrimidine dimer repair, response to UV-C, regulation of DNA repair
InterPro Term DNA_repair_prot_UmuC-like_N, DNA_pol_eta, DNA_repair_prot_UmuC-like, DNA_pol_Y-fam_little_finger
UniProt Accession Q9Y253, Q5JTF2, B4DG64, B3KN75
Gene-Disease Assocation XERODERMA PIGMENTOSUM, VARIANT TYPE; XPV
Search EB-eye ENSG00000170734
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MTAB-25, E-TABM-130, E-TABM-145, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-19639, E-MTAB-62, E-GEOD-7182, E-GEOD-4219, ... (33 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
MOLT4
2
E-MTAB-62, E-MTAB-37
SW480
2
E-MEXP-1014, E-MTAB-37
primary pancreatic ductal adenocarcinoma
1
E-MEXP-2826
380 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (38 experiments)

Factor Value U/D Experiments
centroblast
2
E-GEOD-15271, E-TABM-702
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
basal cell
1
E-GEOD-3998
wild_type
1
E-GEOD-20193
CXCR5(hi)ICOS(hi) CD4 T cell
1
E-MEXP-750
adult choroid from 76 y.o. donor
1
E-GEOD-18811
74 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-1869, E-MEXP-2069, ... (47 experiments)

Factor Value U/D Experiments
melanoma
2
E-MTAB-37, E-GEOD-7307
colon carcinoma
2
E-MTAB-37, E-MTAB-62
glioblastoma
2
E-GEOD-4290, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
control
1
2
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121
superficial transitional cell carcinoma without surrounding carcinoma in situ lesion
1
E-GEOD-3167
137 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, ... (20 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
MK887
1
E-GEOD-3202
nickel(II) chloride hexahydrate
1
E-GEOD-6907
no estradiol
1
E-GEOD-20081
phoshate buffered saline
1
E-GEOD-3720
FLAP
1
1
E-GEOD-3202
29 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
75
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363, E-GEOD-18995, ... (6 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (6 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-GEOD-17476, E-TABM-868, E-TABM-601, E-MEXP-1838, E-MEXP-1403, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-GEOD-5764, E-MEXP-2069, E-MEXP-1648, E-TABM-26, ... (30 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-43, E-TABM-276

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Processing time: 0.301 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM